Rybelsus Novo Nordisk - Search News

Ozempic, Wegovy face US Medicare price negotiations

Reuters on MSN · 2d

US targets Novo Nordisk's Ozempic and Wegovy for Medicare price talks

Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for Medicare price negotiations for 2027, the U.S. government said on Friday. Other drugs on the list include Pfizer's cancer drugs Ibrance and Xtandi,

BioPharma Dive · 2d

Medicare will negotiate Novo’s GLP-1 drug price. Here’s what that means for Ozempic, Wegovy.

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Business Insider · 2d

JPMorgan says Novo’s Ozempic, Rybelsus inclusion in price negotiations expected

After the Centers for Medicare & Medicaid Services announced the selection of 15 additional drugs covered under Medicare Part D for price

pharmaphorum23h

High-dose semaglutide ramps up weight loss, says Novo

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

2don MSN

Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Novo Nordisk touts 'superior' weight loss results in study of high-dose Wegovy

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results